Exploring Brain Metastasis in EGFR-Mutated Non-Small Cell Lung Cancer Patients: Correlation, Detection and Treatment Strategies

Fang T, Liu J, Xiang Y, Zeng L and Lu K

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, China

^*Correspondance to: Kaihua Lu 

 PDF  Full Text Review Article | Open Access

Abstract:

Non-Small Cell Lung Cancer (NSCLC) is a common type of lung cancer, and Epidermal Growth Factor Receptor (EGFR) mutation is a key subtype. NSCLC patients with EGFR mutations generally show better responses to targeted therapy; however, brain metastasis remains a clinical challenge in this patient population. This review aims to delve into the correlation, diagnostic methods, and treatment strategies of EGFR mutations and brain metastasis in NSCLC patients. Firstly, we discuss the correlation between EGFR mutations and the incidence of brain metastasis as well as the survival time of NSCLC patients. We analyze the differences that EGFR mutations bring to the detection of NSCLC patients currently. In terms of treatment, we discuss various options such as surgical resection, radiotherapy, and drug therapy, as well as the pros and cons and potential side effects of these treatment methods. Overall, the management of brain metastasis in NSCLC patients with EGFR mutations faces multiple challenges, but through in-depth research into the specificity of the EGFR signaling pathway and the molecular mechanisms of brain metastasis, we can move towards more effective prevention and treatment strategies.

Keywords:

Cite the Article:

Fang T, Liu J, Xiang Y, Zeng L, Lu K. Exploring Brain Metastasis in EGFRMutated Non-Small Cell Lung Cancer Patients: Correlation, Detection and Treatment Strategies. Clin Oncol. 2023;8:2038..